Structural framework of c-Src activation by integrin β3

Blood

Volumn 121, Issue 4, 2013, Pages 700-706

  Xiao, Run ^a,b   Xi, Xiao Dong ^a   Chen, Zhu ^a,b   Chen, Sai Juan ^a,b   Meng, Guoyu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ARGINYLGLYCYLTHREONINE; BETA3 INTEGRIN; PROTEIN SH3; PROTEIN TYROSINE KINASE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

EID: 84873053904     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-440644     Document Type: Article

References (38)

1. Mathew S, George SP, Wang Y, et al. Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J Biol Chem. 2008;283(33):22709-22722.
2. Roskoski R Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun. 2004;324(4):1155-1164.
3. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223(1):14-26.
4. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587-595.
5. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008;8(4):427-432.
6. Sicheri F, Kuriyan J. Structures of Src-family ty-rosine kinases. Curr Opin Struct Biol. 1997;7(6): 777-785.
7. Kaplan JM, Varmus HE, Bishop JM. The src protein contains multiple domains for specific attachment to membranes. Mol Cell Biol. 1990;10(3): 1000-1009.
8. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 1997;385(6617):595-602.
9. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 1997; 385(6617):602-609.
10. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859-871.
11. Lee CH, Saksela K, Mirza UA, Chait BT, Kuriyan J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell. 1996; 85(6):931-942.
12. Moarefi I, LaFevre-Bernt M, Sicheri F, et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 1997; 385(6617):650-653.
13. Lerner EC, Smithgall TE. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat Struct Biol. 2002;9(5):365-369.
14. Zheng XM, Wang Y, Pallen CJ. Cell transformation and activation of pp60c-src by overexpres-sion of a protein tyrosine phosphatase. Nature. 1992;359(6393):336-339.
15. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 2001;105(1):115-126.
16. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 1996; 384(6608):484-489.
17. LaFevre-Bernt M, Sicheri F, Pico A, Porter M, Kuriyan J, Miller WT. Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue. J Biol Chem. 1998;273(48):32129- 32134.
18. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell. 1999;3(5): 629-638.
19. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A. 2003;100(23): 13298-13302.
20. Arias-Salgado EG, Lizano S, Shattil SJ, Ginsberg MH. Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain. J Biol Chem. 2005;280(33):29699-29707.
21. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-647.
22. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010;11(4):288-300.
23. Metcalf DG, Moore DT, Wu Y, et al. NMR analysis of the alphaIIb beta3 cytoplasmic interaction suggests a mechanism for integrin regulation. Proc Natl Acad Sci U S A. 2010;107(52):22481-22486.
24. Su X, Mi J, Yan J, et al. RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood. 2008;112(3):592-602.
25. Ablooglu AJ, Kang J, Petrich BG, Ginsberg MH, Shattil SJ. Antithrombotic effects of targeting al-phaIIbbeta3 signaling in platelets. Blood. 2009; 113(15):3585-3592.
26. Musacchio A, Saraste M, Wilmanns M. Highresolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich pep-tides. Nat Struct Biol. 1994;1(8):546-551.
27. Kami K, Takeya R, Sumimoto H, Kohda D. Diverse recognition of non-PxxP peptide ligands by the SH3 domains from p67(phox), Grb2 and Pex13p. EMBO J. 2002;21(16):4268-4276.
28. Huveneers S, van den Bout I, Sonneveld P, Sancho A, Sonnenberg A, Danen EH. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src. Cancer Res. 2007; 67(6):2693-2700.
29. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin alpha(v) beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15(10):1163-1169.
30. Huveneers S, Danen EH. The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer. Sci World J. 2010;10:1100-1105.
31. Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin alphaIIb beta3 transmembrane-cytoplasmic heterocomplex provides insight into integ-rin activation. Proc Natl Acad Sci U S A. 2009; 106(42):17729-17734.
32. Erpel T, Superti-Furga G, Courtneidge SA. Muta-tional analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra-and intermolecular interactions. EMBO J. 1995;14(5):963-975.
33. Ylanne J, Chen Y, O'Toole TE, Loftus JC, Takada Y, Ginsberg MH. Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol. 1993; 122(1):223-233.
34. Lee CH, Leung B, Lemmon MA, et al. Asingle amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J. 1995;14(20):5006-5015.
35. Shattil SJ. Integrins and Src: dynamic duo of adhesion signaling. Trends Cell Biol. 2005;15(8): 399-403.
36. Arias-Salgado EG, Haj F, Dubois C, et al. PTP-1B is an essential positive regulator of platelet integ-rin signaling. J Cell Biol. 2005;170(5):837-845.
37. DeLano WL. The PyMOL Molecular Graphics System. Palo Alto, CA: DeLano Scientific; 2002.
38. Engh RA, Huber R. Accurate bond and angle parameters for x-ray protein structure refinement. Acta Crystallogr. 1991;A47:392-400.